Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. 

You may not take part in this study if:

  • You are outside of the limits for this study of age (18-45 years; 18-55 years for Japanese/Chinese participants and MD-part) or Body Mass Index (16 - 32 kg/m2) or below the limit for weight (minimum of 45 kg).
  • For the Japanese cohort: You do not have 4 biological Japanese grandparents who were born in Japan.
  • For the Chinese cohort: You do not have 4 biological Chinese grandparents who were born in mainland China.

 

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process. 
 

See calendar

Condition

Healthy

Age

18 to 45

Sex

Male/female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium. This study will have 2 Parts:

- A part with Single Ascending (escalating) doses, referred to as the ‘SAD Part’

- A part with Multiple doses, referred to as the ‘MD Part’

The study will last

  • for the SAD Part: about 18 weeks or 19 weeks if a priming dose is implemented;
  • for the MD Part: about 26 weeks or 27 weeks if a priming dose is implemented;
  • for the optional Cohort 11 and Cohort 12: up to about 27 weeks.

You will be screened within 28 days prior to the first dose of study intervention.

Throughout the study, staff will closely monitor your health status and collect data.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
 

How long is the study?

Approximately 18 weeks

Compensation

Up to € 7.190, plus travel fees

Interested in participating?

Whether you are new to clinical research or already in our database, if you’d like to subscribe for this study, please use the PCRU Chatbot Charlie at the bottom right of the screen.